GlaxoSmithKline has spent 20 years trying to develop an improved vaccine for tuberculosis, and new data for its lead candidate M72/AS01E suggests it is getting closer to a breakthrough in the disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,